Search Results - "Heymach, J.V."

RAD50 Expression Predicts for Locoregional Failure and Distant Metastatic Recurrence After Postoperative Radiation Therapy in Resected Non-Small Cell Lung Cancer by Lin, S.H, Gudikote, J, Giri, U, Fujimoto, J, Wang, J, Wei, C, Chen, H, Farnia, B, Gomez, D.R, Story, M.D, Komaki, R.U, Swisher, S.G, Wistuba, I, Heymach, J.V

Get full text

Nadir White Blood Cell, Absolute Neutrophil, and Absolute Lymphocyte Counts During Concurrent Chemoradiation Therapy Are Associated With Worse Outcomes in Patients With Limited-Stage Small Cell Lung Cancer by Wei, X, Allen, P.K, Liao, Z, Skinner, H.D, Welsh, J.W, Gomez, D.R, Nguyen, Q, Lin, S.H, Heymach, J.V, Cox, J.D, Komaki, R.U

Get full text

High Throughput Clonogenic Survival Screen Identifies Novel Radiation Sensitizers for K- ras Mutant Non-Small Cell Lung Cancer by Lin, S.H, Zhang, J, Giri, U, Stephan, C, Sobieski, M.M, Nguyen, N, Davies, P, Komaki, R, Yoo, S.S, Heymach, J.V

Get full text

Elevated Serum HGF Is Associated With Radioresistance and Local Recurrence in Non-Small Cell Lung Cancer by Soh, H.E, Bhardwaj, V, Cortez, M.A, Allen, P.K, Heymach, J.V, Meyn, R, Xia, D, Gomez, D.R, Skinner, H.J, Welsh, J.W

Get full text

Dosimetric Impact of Induction Chemotherapy on Subsequent Radiation Treatment Planning in Patients With Inoperable Non-Small Cell Lung Cancer by Grant, J.D, Sobremonte, A, Hillebrandt, E, Allen, P.K, Lin, S.H, Chang, J.Y, Komaki, R, Liao, Z, Heymach, J.V, Gomez, D

Get full text

388 An integrated molecular analysis of lung adenocarcinomas identifies potential therapeutic targets among TTF1-negative tumors by Cardnell, R.J, Behrens, C, Diao, L, Fan, Y, Tang, X, Minna, J.D, Mills, G.B, Heymach, J.V, Wistuba, I.I, Wang, J, Byers, L.A

Get full text

435 A pan-cancer tumor-derived epithelial-to–mesenchymal transition (EMT) signature determines patterns of drug sensitivity and enrichment in immune target expression following EMT by Mak, M.P, Tong, P, Diao, L, Ng, P.K.S, Fan, Y, Cardnell, R.J, Gibbons, D.L, William, W.N, Heymach, J.V, Coombes, K.R, Byers, L.A, Wang, J

Get full text

Nadir White Blood Cell, Absolute Neutrophil, and Absolute Lymphocyte Counts During Concurrent Chemoradiation Therapy Are Associated With Worse Outcomes in Patients With Limited-Stage Small Cell Lung Cancer by Wei, X, Allen, P.K, Liao, Z, Skinner, H.D, Welsh, J.W, Gomez, D.R, Nguyen, Q, Lin, S.H, Heymach, J.V, Cox, J.D, Komaki, R.U

Get full text

Predictors of Brain Metastasis After Prophylactic Cranial Irradiation for Limited-Stage Small Cell Lung Cancer by Komaki, R.U, Allen, P.K, Wei, X, Liao, Z, Skinner, H.D, Welsh, J.W, Gomez, D.R, Nguyen, Q, Lin, S.H, Heymach, J.V, Cox, J.D

Get full text

Implications of KRAS Mutations on Outcomes in Non-small Cell Lung Cancer Treated With Radiation Therapy by Welsh, J.W, Likacheva, A, Byers, L.A, Bhardwaj, V, Diao, L, Wang, J, Ang, K, Komaki, R, Kim, E, Heymach, J.V

Get full text

Patient Selection for Treatment Modality in Stage III Non-small Cell Lung Cancer: A Population-based Analysis by Gomez, D.R, Liao, K, Chang, J.Y, Liao, Z, Shirvani, S.M, Komaki, R, Welsh, J.W, Swisher, S.G, Heymach, J.V, Smith, B.D

Get full text

Treatment Modality and Other Prognostic Factors for Overall Survival in Stage III Non-small Cell Lung Cancer (NSCLC): A Population-based Analysis by Gomez, D.R, Liao, K, Chang, J.Y, Liao, Z, Shirvani, S.M, Komaki, R, Welsh, J.W, Heymach, J.V, Swisher, S.G, Smith, B.D

Get full text

Limited-Stage Small Cell Lung Cancer in the Contemporary Period: Impact of New Technologies on Outcomes by Juloori, A, Shirvani, S.M, Allen, P, Komaki, R, Liao, Z, Welsh, J, Gomez, D, Heymach, J.V, Chang, J.Y

Get full text

OC-0499 PROGNOSTIC IMPACT OF RADIATION THERAPY TO THE PRIMARY TUMOR IN PATIENTS WITH OLIGOMETASTATIC LUNG CANCER by Gomez, D.R, Guerra, J.L. Lopez, Zhuang, Y, Hong, D.S, Heymach, J.V, Swisher, S.G, Lin, S.H, Komaki, R, Cox, J.D, Liao, Z

Get full text

Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC) by Cascone, T., William, W.N., Weissferdt, A., Leung, C.H., Federico, L., Haymaker, C., Bernatchez, C., Fossella, F.V., Mott, F.E., Papadimitrakopoulou, V.A., Byers, L., Lam, V.K., Godoy, M.C., Carter, B., Lee, J.J., Vaporciyan, A., Gibbons, D.L., Swisher, S.G., Heymach, J.V., Sepesi, B.

Get full text

1404 POSTER DISCUSSION Baseline (BL) IL-6, IL-8, and VEGF as Predictive and Prognostic Markers for Overall Survival (OS) in Metastatic Renal Cell Carcinoma (mRCC) Patients (pts) Treated in a Phase III Trial of Pazopanib (PAZO) Versus Placebo (PL) by Liu, Y, Tran, H.T, Lin, Y, Martin, A.M, Zurita, A, Sternberg, C.N, Team, V.E.G, Amado, R, Pandite, L.N, Heymach, J.V

Get full text

The Advantage of using PET SUV to Evaluate Tumor Response by RECIST Criteria in Patients with Stage IIIA/B Non-small Cell Lung Cancer (NSCLC) after Concurrent Chemotherapy and Tarceva with Radiotherapy by Wei, X, Allen, P.K, Blumenschein, G, Hong, W.K, Herbst, R.S, O'Reily, M, Heymach, J.V, Erasmus, J, Lee, J, Komaki, R

Get full text

Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression by Aguilar, E.J., Ricciuti, B., Gainor, J.F., Kehl, K.L., Kravets, S., Dahlberg, S., Nishino, M., Sholl, L.M., Adeni, A., Subegdjo, S., Khosrowjerdi, S., Peterson, R.M., Digumarthy, S., Liu, C., Sauter, J., Rizvi, H., Arbour, K.C., Carter, B.W., Heymach, J.V., Altan, M., Hellmann, M.D., Awad, M.M.

“…In non-small-cell lung cancers with programmed death-ligand 1 (PD-L1) expression on ≥50% of tumor cells, first-line treatment with the PD-1 inhibitor…”
Get full text

A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors by Ferrarotto, R., Eckhardt, G., Patnaik, A., LoRusso, P., Faoro, L., Heymach, J.V., Kapoun, A.M., Xu, L., Munster, P.

“…Brontictuzumab is a monoclonal antibody that targets Notch1 and inhibits pathway activation. The purpose of this first-in-human study was to determine the…”
Get full text

LBA59 Associations of ctDNA clearance and pathological response with neoadjuvant treatment in patients with resectable NSCLC from the phase III AEGEAN trial by Reck, M., Gale, D., Harpole, D., Taube, J.M., Mitsudomi, T., Hochmair, M.J., Winder, T., Zhu, Z., Lai, Z., Stewart, R., Hodgson, D.R., Doherty, G.J., Heymach, J.V.

Get full text